Arch Therapeutics, Inc. (OTCMKTS:ARTH) Short Interest Up 40.3% in September

Arch Therapeutics, Inc. (OTCMKTS:ARTH) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 17,400 shares, a growth of 40.3% from the September 15th total of 12,400 shares. Based on an average daily trading volume, of 27,200 shares, the short-interest ratio is presently 0.6 days.

Arch Therapeutics Stock Down 24.9 %

Shares of ARTH opened at $0.32 on Friday. The stock’s 50 day moving average is $0.57 and its two-hundred day moving average is $0.93. Arch Therapeutics has a twelve month low of $0.17 and a twelve month high of $18.00.

Arch Therapeutics (OTCMKTS:ARTH) last issued its earnings results on Monday, August 19th. The biotechnology company reported ($1.44) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.